Scarica l'app Stockscreener
27.50
1.03%
0.28
Dopo l'orario di chiusura:
27.50
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché GMAB Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$27.22
Aprire:
$26.55
Volume 24 ore:
1.08M
Relative Volume:
0.62
Capitalizzazione di mercato:
$16.88B
Reddito:
$3.73B
Utile/perdita netta:
$965.82M
Rapporto P/E:
17.76
EPS:
1.5481
Flusso di cassa netto:
$1.13B
1 W Prestazione:
+5.65%
1M Prestazione:
-7.25%
6M Prestazione:
-14.38%
1 anno Prestazione:
+46.12%
Intervallo 1D:
$26.55
$27.53
Intervallo di 1 settimana:
$25.76
$27.53
Portata 52W:
$17.23
$35.43
Genmab Adr Stock (GMAB) Company Profile
Compare GMAB vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GMAB
Genmab Adr
|
27.50 | 16.88B | 3.73B | 965.82M | 1.13B | 1.5481 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Genmab Adr Stock (GMAB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-27 | Iniziato | Wolfe Research | Outperform |
| 2026-03-02 | Iniziato | Wells Fargo | Overweight |
| 2026-02-17 | Ripresa | Jefferies | Buy |
| 2026-02-17 | Ripresa | Morgan Stanley | Equal-Weight |
| 2025-09-23 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2025-04-01 | Downgrade | Bernstein | Mkt Perform → Underperform |
| 2025-03-11 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2025-02-13 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-10-08 | Iniziato | Redburn Atlantic | Buy |
| 2024-09-04 | Ripresa | Morgan Stanley | Equal-Weight |
| 2024-08-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-07-15 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-02-23 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2024-01-22 | Downgrade | Citigroup | Neutral → Sell |
| 2023-12-06 | Aggiornamento | UBS | Neutral → Buy |
| 2023-11-10 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2023-11-08 | Aggiornamento | DNB Markets | Sell → Buy |
| 2023-10-18 | Iniziato | Exane BNP Paribas | Underperform |
| 2023-09-06 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-08-24 | Iniziato | BTIG Research | Buy |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-05-31 | Iniziato | UBS | Neutral |
| 2023-05-12 | Iniziato | Morgan Stanley | Underweight |
| 2022-12-20 | Downgrade | Citigroup | Buy → Neutral |
| 2022-11-14 | Iniziato | William Blair | Mkt Perform |
| 2022-11-11 | Downgrade | Deutsche Bank | Buy → Hold |
| 2022-06-24 | Iniziato | BMO Capital Markets | Market Perform |
| 2022-05-02 | Iniziato | Cowen | Market Perform |
| 2022-03-16 | Aggiornamento | UBS | Neutral → Buy |
| 2022-01-31 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2022-01-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-12-01 | Iniziato | Berenberg | Sell |
| 2021-09-16 | Downgrade | Jefferies | Buy → Hold |
| 2021-09-07 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2021-08-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2021-04-20 | Iniziato | Deutsche Bank | Buy |
| 2021-01-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-09-23 | Downgrade | Bryan Garnier | Neutral → Sell |
| 2020-09-08 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-06-25 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2020-04-23 | Iniziato | Credit Suisse | Outperform |
| 2020-02-24 | Reiterato | H.C. Wainwright | Buy |
| 2020-01-13 | Iniziato | SunTrust | Buy |
| 2019-12-12 | Downgrade | Deutsche Bank | Buy → Hold |
| 2019-09-13 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-09-12 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-08-12 | Iniziato | Guggenheim | Buy |
| 2019-08-12 | Iniziato | Morgan Stanley | Overweight |
| 2019-08-12 | Iniziato | RBC Capital Mkts | Outperform |
Mostra tutto
Genmab Adr Borsa (GMAB) Ultime notizie
827,217 Shares in Genmab A/S Sponsored ADR $GMAB Bought by Perpetual Ltd - MarketBeat
JPMorgan Chase & Co. Decreases Position in Genmab A/S Sponsored ADR $GMAB - MarketBeat
Arrowpoint Investment Partners Singapore Pte. Ltd. Takes Position in Genmab A/S Sponsored ADR $GMAB - MarketBeat
Major Shareholder Announcement - GlobeNewswire Inc.
Terra Nova Asset Management LLC Invests $1.87 Million in Genmab A/S Sponsored ADR $GMAB - MarketBeat
This Honeywell Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Sahm
Genmab ADR shows improved relative strength; still shy of benchmark - MSN
Genmab A/S Touts Strong 2025, Teases Catalyst-Heavy 2026 With Potential 2027 Launches - Yahoo Finance
Alliancebernstein L.P. Has $335.96 Million Stock Holdings in Genmab A/S Sponsored ADR $GMAB - MarketBeat
Genmab A/S Sponsored ADR (NASDAQ:GMAB) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Genmab A/ S: The Biotech Stock Gen Z Is Quietly Watching - AD HOC NEWS
Russell Investments Group Ltd. Has $25.23 Million Holdings in Genmab A/S Sponsored ADR $GMAB - MarketBeat
First Trust Advisors LP Sells 82,922 Shares of Genmab A/S Sponsored ADR $GMAB - MarketBeat
GMAB Earnings History & Surprises | EPS & Revenue Results | GENMAB A/S -SP ADR (NASDAQ:GMAB) - ChartMill
Genmab (GMAB) Upgraded to Strong Buy: Here's Why - MSN
Stocks With Rising Relative Strength: Genmab ADR - Investor's Business Daily
Genmab ADR Shows Improved Relative Strength; Still Shy Of Benchmark - Investor's Business Daily
What is HC Wainwright’s Forecast for Genmab A/S Q1 Earnings? - Defense World
GENMAB A/S -SP ADR (NASDAQ:GMAB) Emerges as a Peter Lynch-Style GARP Investment - ChartMill
Genmab (GMAB) Reports 19% Revenue Growth to $3.7B in 2025 Driven by Proprietary Medicine Sales - Finviz
Genmab A/S (NASDAQ:GMAB) Given New $40.00 Price Target at HC Wainwright - Defense World
Top 3 Health Care stocks That Could Lead To Your Biggest Gains In Q1 - Sahm
Genmab A/S Sponsored ADR (NASDAQ:GMAB) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Genmab A/S (NASDAQ:GMAB) Coverage Initiated by Analysts at Jefferies Financial Group - Defense World
Genmab A/S Q4 Earnings Call Highlights - Yahoo Finance
Genmab A/S (NASDAQ:GMAB) Given Equal Weight Rating at Morgan Stanley - Defense World
Genmab A/S Sponsored ADR (NASDAQ:GMAB) Sees Significant Decrease in Short Interest - MarketBeat
279,932 Shares in Genmab A/S Sponsored ADR $GMAB Bought by Cibc World Market Inc. - MarketBeat
Is the Options Market Predicting a Spike in Genmab Stock? - TradingView
H.C. Wainwright Bullish on Genmab A/S (GMAB) on Robust Sales for DARZALEX - Finviz
Envestnet Asset Management Inc. Purchases 60,336 Shares of Genmab A/S Sponsored ADR $GMAB - MarketBeat
RFG Advisory LLC Takes $1.30 Million Position in Genmab A/S Sponsored ADR $GMAB - MarketBeat
Where is Genmab A/S (GMAB) Headed According to Wall Street? - Finviz
Oppenheimer Asset Management Inc. Acquires 61,311 Shares of Genmab A/S Sponsored ADR $GMAB - MarketBeat
Genmab A/S (NASDAQ:GMAB): A GARP Case Study in Affordable Biotech Growth - ChartMill
Federated Hermes Inc. Makes New Investment in Genmab A/S Sponsored ADR $GMAB - MarketBeat
What is HC Wainwright’s Estimate for Genmab A/S Q4 Earnings? - Defense World
What is HC Wainwright's Estimate for Genmab A/S Q4 Earnings? - MarketBeat
EPKINLY Trial Results Prompt Price Target Cut for Genmab (GMAB) - Finviz
HC Wainwright Boosts Earnings Estimates for Genmab A/S - MarketBeat
GENMAB A/S (NASDAQ:GMAB) Stands Out as a Peter Lynch-Style GARP Investment - Chartmill
Genmab A/S (NASDAQ:GMAB) Shares Gap DownHere's What Happened - MarketBeat
GENMAB A/S -SP ADR (NASDAQ:GMAB) Combines Strong Growth with Bullish Technical Formation - Chartmill
GENMAB A/S (NASDAQ:GMAB) Presents a Compelling Blend of Strong Fundamentals and Bullish Technicals - ChartMill
Genmab A/S Sponsored ADR (NASDAQ:GMAB) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Genmab A/S Sponsored ADR (NASDAQ:GMAB) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Alkermes Stock Earns Technical Rating Upgrade - Investor's Business Daily
Genmab A/S (GMAB) Shares Gain Analyst Support as Deutsche Bank Sees Oncology Upside - Finviz
Ascendis Pharma ADR shows rising price performance with jump to 83 RS rating - MSN
Genmab Adr Azioni (GMAB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):